Magdi Wassef, MD
Internal Medicine · Southaven, MSNPI 1275638363
Payments from drug & device makers
Across 352 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$918
- Lilly USA, LLC$749
- Boehringer Ingelheim$593
- Bayer$585
- AstraZeneca$464
- GSK$392
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,79599%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $918 |
| Lilly USA, LLC | 53 | $749 |
| Boehringer Ingelheim | 39 | $593 |
| Bayer | 33 | $585 |
| AstraZeneca | 29 | $464 |
| GSK | 24 | $392 |
| Astellas Pharma US Inc | 17 | $347 |
| Johnson & Johnson | 21 | $299 |
| Abbott | 15 | $294 |
| Sumitomo Pharma America, Inc. | 9 | $186 |
| Intuitive Surgical | 2 | $173 |
| Sanofi-aventis U.S. LLC | 8 | $131 |
| Otsuka America Pharmaceutical, Inc. | 5 | $125 |
| AbbVie(2 entities) | 6 | $119 |
| Pfizer | 7 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $95 |
| Phathom Pharmaceuticals, Inc. | 4 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Amgen | 1 | $19 |
| Novartis | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Merck | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,870 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 192 | $265,230 |
| MounjaroTirzepatide | 193 | $260,257 |
| OzempicSemaglutide | 120 | $184,881 |
| EliquisApixaban | 119 | $124,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 120 | $122,327 |
| FarxigaDapagliflozin Propanediol | 52 | $45,565 |
| XareltoRivaroxaban | 31 | $39,503 |
| LinzessLinaclotide | 37 | $36,689 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $33,718 |
| GemtesaVibegron | 39 | $33,681 |
| JanuviaSitagliptin Phosphate | 22 | $27,320 |
| TrulicityDulaglutide | 18 | $26,120 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $23,655 |
| EntrestoSacubitril/Valsartan | 13 | $18,254 |
| InvokanaCanagliflozin | 14 | $17,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $749 | $286,378211 claims |
| Boehringer IngelheimJardiance | $593 | $265,230192 claims |
| Novo NordiskOzempic | $918 | $184,881120 claims |
| PfizerEliquis | $108 | $124,969119 claims |
| GSKTrelegy Ellipta | $392 | $122,327120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $464 | $57,97468 claims |
| Johnson & JohnsonXarelto, Invokana | $299 | $56,87845 claims |
| MerckJanuvia, Janumet Xr | $12 | $50,97549 claims |
| AbbVieLinzess | $119 | $36,68937 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $186 | $33,68139 claims |
| NovartisEntresto | $18 | $18,25413 claims |
| Sanofi-aventis U.S. LLCLantus | $131 | $5,86330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Southaven
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.